Chemical Synthesis of Radioligands for Therapeutics

Dear Colleagues,

This Special Issue is dedicated to showcasing the latest advancements in the chemical synthesis of radioligands for therapeutic applications. As the field of nuclear medicine expands, the demand for novel radioligands that can accurately diagnose and monitor therapeutic outcomes is at an all-time high. Researchers and chemists are developing innovative synthetic methodologies to create radioligands with higher specificity, stability, and bioavailability.

We are pleased to invite you to submit a report on the synthesis of radioligands designed for better brain barrier permeability, targeting of specific receptors or enzymes implicated in various diseases, and improved in vivo stability. Through this Special Issue, we aim to bridge the gap between chemical synthesis and clinical application, ultimately contributing to the advancement of personalized medicine.

This Special Issue aims to explore cutting-edge research that addresses the challenges in synthesizing radioligands capable of targeting a diverse range of biological targets. We will feature studies that highlight improved synthetic routes, which enhance the efficacy and reduce the toxicity of radioligands. Contributions may include the development of radioligands for emerging therapeutic targets, advancements in radiochemistry that expand the utility of PET and SPECT imaging, and novel strategies to optimize radioligand production for clinical use.

In this Special Issue, original research articles and reviews on the recent developments in radioligand synthesis for therapeutic applications, particularly those that demonstrate translational potential, are welcomed.

We look forward to receiving your contributions.

Dr. Changning Wang
Guest Editor

Dr. Yulong Xu
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• radioligands
• synthesis
• biological targets
• clinical application
• PET
• SPECT
• imaging